Thu, October 18, 2012
Wed, October 17, 2012

Christopher Raymond Maintained (BIIB) at Buy with Increased Target to $179 on, Oct 18th, 2012

  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. th-increased-target-to-179-on-oct-18th-2012.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Christopher Raymond of Piper Sandler, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $159 to $179 on, Oct 18th, 2012.

Christopher has made no other calls on BIIB in the last 4 months.



There are 5 other peers that have a rating on BIIB. Out of the 5 peers that are also analyzing BIIB, 1 agrees with Christopher's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Jay Olson of "Oppenheimer" Downgraded from Buy to Hold on, Thursday, October 4th, 2012


These are the ratings of the 4 analyists that currently disagree with Christopher


  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $175 on, Monday, October 8th, 2012
  • Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $160 on, Thursday, September 6th, 2012
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $150 on, Wednesday, July 25th, 2012
  • Geoffrey Porges of "Leerink Swann" Initiated at Buy on, Monday, July 23rd, 2012